2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Blood Banking, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

2576 Spectral flowcytometry based BH3 profiling to interogate venetoclax sensitivity in infant ALL

Thomas Hogan, Haley Goodrow2, Fatemeh Alikarami, PhD3, Trang Nguyen4, James LaBelle, MD, PhD5, Kathrin Bernt, MD6
1 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
3 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The University of Chicago, Chicago, United States
6 The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

KMT2A-rearranged infant ALL, which makes up 70% of infant ALL, is a notoriously difficult-to-treat hematopoietic malignancy. Recently, the standard of care for infant ALL has changed to include the CD3:CD19 T cell engager blinatumomab, which has improved outcomes. Despite this advance, the outcomes for infants remain below outcomes for children over the age of 1. There is thus an urgent need to identify additional effective therapeutic modalities. Furthermore, given the critical importance of T-cell engager immunotherapy, the effect of novel agents on the T-cell compartment needs to be taken into consideration.

Strong mechanistic data supports the integration of the BCL-2 inhibitor venetoclax into the infant ALL treatment regimen. BCL-2 is a transcriptional target of the KMT2A rearrangement. Furthermore, venetoclax is effective against KMT2A-rearranged cell lines and patient samples in small preclinical cohorts. Furthermore, emerging data suggests that venetoclax is relatively non-toxic to T-cells. Venetoclax is currently being studied in clinical trials in combination with chemotherapy for children with relapsed acute leukemias, and for infant ALL in the upfront setting.

The clinical use of venetoclax in AML, particularly in elderly / unfit adult patients, has highlighted several mechanisms of resistance. These include RAS pathway mutations, TP53 mutations, as well as a monocytic differentiation, among others. RAS pathway mutations are the most common co-mutations in infant ALL. TP53 mutations and lineage switch to monocytic AML are not infrequently seen at relapse, particularly after immunotherapy. Finally, in two small “real world” studies of pediatric leukemia patients treated with venetoclax and hypomethylating agents, KMT2A-rearrangements were associated with inferior responses (with the caveat of very low numbers). This highlights the need for detailed correlative biology studies of larger patient cohorts to understand determinants of venetoclax response and resistance in infant ALL.

To this end, we have developed a spectral flowcytometry assay that combines dynamic BH3 profiling with the characterization of T-cell subsets. This assay facilitates the concurrent examination of both patient leukemic blasts and T-cells to determine the dependence on BCL-2 family proteins and the sensitivity of these patient samples to venetoclax. This allows us to have a nuanced understanding of the delicate balance of BCL-2 apoptotic priming, BCL-2 inhibition via venetoclax, and the patient’s immune system. We have used this assay to study a cohort of 35 KMT2A-rearranged cell lines and primary patient samples (obtained from a range of sources and mostly, but not exclusively, infants). T-cell subset profiling revealed massively altered T-cell subsets in a subgroup of iALL patients, with an expansion of central memory and effector T-cell populations compared to age matched normal. Preliminary data showed decreased expansion of T-cells from patients with altered profiles in response to CD3:CD28 stimulation, suggesting T-cell dysfunction in this subset of patients. KMT2A-rearranged leukemia cells were sensitive to venetoclax, with substantial inter-patient variability. Typically, leukemic blasts were more sensitive than the same patient’s T-cells.

Our data lends additional support to the ongoing clinical trials that evaluate venetoclax for KMT2A-rearranged leukemias. Furthermore, our assay is well suited for sophisticated correlative biology studies in the context of clinical trials. Serial analysis of blast and T-cell profiles integrated with genomic, phenotypic and outcomes data will serve to delineate determinants of venetoclax efficacy and resistance, as well as the impact of using venetoclax as part of induction chemotherapy on T-cell subsets and fitness, which is of critical importance for post-induction immunotherapy.

Thomas Hogan: No relevant conflicts of interest to declare.